Chromogranin A

ApprovedBiologic

AAsan Medical Center

Chromogranin A is one of 46 biologic programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Pancreatic Neuroendocrine TumorApproved

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Pancreatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

DTIC-Dome

Afinitor

8 3

Sandostatin

Glucophage

Octreotide

Sutent

5 7

FOLFOX

AstraZeneca

Phase 3

1 8

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 9

Ibrance

Pfizer

Phase 2

1 10

Sandostatin

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Neuroendocrine Tumor1 trial

Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors

Unknown status·—·Phase 4·NCT02759718·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chromogranin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chromogranin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chromogranin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asan Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: AAsan Medical Center

Chromogranin A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News